Nycomed Holdings A/S
From Wikipedia, the free encyclopedia
Nycomed Holdings A/S (previously "Hafslund Nycomed") and subsidiaries is a European pharmaceutical company.
Contents |
[edit] Quick facts
- Production takes place in Norway, Denmark, Finland, Austria, Belgium, Germany, Ireland, India, the US and Estonia.
- The company's headquarter lies in Zurich, Switzerland.
- In 2006 total sales were 3,400 million Euros.
- There are about 12,000 employees.
[edit] History
The company was started in Norway in 1874, as an agent of foreign pharmacautical products. In 1913 it started producing generic drugs, among these Globoid (copy of Aspirin). In 1969, the development of the revolutionary radiocontrast agent Omnipaque made the company highly successful. In 1985, Nycomed was purchased by the power company Hafslund, and in 1997 the company merged with British Amersham. In 1999, the company was established under the name Nycomed as an independent company. Nycomed is privately owned primarily by the two private equity investors Nordic Capital and CSFB Alternative Capital. In 2007, Nycomed took over the much larger German pharmaceutical company, Altana Pharma. This acquisition made Nycomed one of the world's 25 largest pharmaceutical companies.
Since then it has pursued a strategy of licensing new medicines from research companies and introducing them to Europe. The company provides specialist/hospital products throughout Europe. General Practitioner and pharmacy medicines are also provided but in selected countries. Today the company is active throughout Europe and continues to expand into new markets.
